Novel antigens for cancer immunotherapy – a way to enhance effectiveness?
Research is ongoing to revisit the classic neoantigen approach that may better interpret the complexity of the immune system
Actinium-225 shows clinical activity in metastatic castration-resistant prostate cancer
Survival benefits of the radioligand therapy needs to be confirmed in further studies
Most combinations of cancer drugs have additive, but not synergistic efficacy
A study describes an additivity model that can be used to predict the likelihood of success or failure of combination therapies in phase III trials
TILs show long-term efficacy in melanoma, but predicting treatment response is still a challenge
After proof of efficacy in patients with melanoma in a clinical trial, major efforts are now directed to make the use of TILs easier and safer in clinical practice.
Blocking GDF-15 may be promising to overcome resistance to immunotherapy
A study reports evidence of antitumour activity by combining a GDF-15 neutralising antibody with PD-1 inhibition in cancers that are refractory/relapsed to immune checkpoint inhibitors
Lenvatinib plus pembrolizumab does not improve outcomes in NSCLC
Certain immunotherapy combinations that are effective in selected solid tumours may not be effective in lung cancer without targetable genetic alterations.
Additional data confirm the promise of combination therapies for EGFR-mutated NSCLC
Analysis from MARIPOSA-2 and FLAURA2 trials show a potential change of treatment paradigm in both first- and second-line settings
Targeted therapy shows early promise in EBV-positive nasopharyngeal carcinoma
In an early-phase study, the selective inhibitor nanatinostat was well tolerated with evidence of antitumour activity in combination with antiviral therapy
Amivantamab combination therapies emerge as new options for EGFR-mutated advanced NSCLC
Clinically meaningful improvements over standard care were observed in both first and second line, as reported in the MARIPOSA and MARIPOSA-2 phase III trials
177Lu-PSMA-617 improves rPFS in taxane-naïve metastatic castration-resistant prostate cancer
However, lack of OS benefit limits the clinical impact of the findings from the PSMAfore trial